pseudolongum could not exhibit anti-tumor immunity against colon cancer, bladder cancer and melanoma, whereas its combination with anti-CTLA-4 treatment significantly decreases tumor growth compared to anti-CTLA-4 treatment alone by increasing IFN-γ production mediated via higher spleen TH1 cell activation [66]. The gene discussed is CTLA4; the disease is urinary bladder carcinoma.